The Hemophagocytic Lymphohistiocytosis drugs in development market research report provides comprehensive information on the therapeutics under development for Hemophagocytic Lymphohistiocytosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemophagocytic Lymphohistiocytosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemophagocytic Lymphohistiocytosis and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Hemophagocytic Lymphohistiocytosis by 17 companies/universities/institutes. The top development phase for Hemophagocytic Lymphohistiocytosis is preclinical with six drugs in that stage. The Hemophagocytic Lymphohistiocytosis pipeline has 15 drugs in development by companies and two by universities/ institutes. Some of the companies in the Hemophagocytic Lymphohistiocytosis pipeline products market are: Innovent Biologics, Cincinnati Children’s Hospital Medical Center and Atara Biotherapeutics.
The key targets in the Hemophagocytic Lymphohistiocytosis pipeline products market include Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2), Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), and Interferon Gamma (Immune Interferon or IFNG).
The key mechanisms of action in the Hemophagocytic Lymphohistiocytosis pipeline product include Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Inhibitor with three drugs in Phase II. The Hemophagocytic Lymphohistiocytosis pipeline products include six routes of administration with the top ROA being Intravenous and five key molecule types in the Hemophagocytic Lymphohistiocytosis pipeline products market including Monoclonal Antibody, and Small Molecule.
Hemophagocytic Lymphohistiocytosis overview
Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic or haemophagocytic syndrome is an uncommon hematologic disorder and is a life-threatening disease of severe hyperinflammation caused by uncontrolled proliferation of benign lymphocytes and macrophages that secrete high amounts of inflammatory cytokines. It is seen more often in children than in adults. HLH results from immune over-activation owing to some combination of inappropriate immunologic (CD8+ and macrophage) feedback mechanisms and chronic inflammation.
For a complete picture of Hemophagocytic Lymphohistiocytosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
